Prices delayed by at least 15 minutes | Print
Novacyt S.A. (NCYT)
EUR1/15TH (CDI)Open
39.60p
Previous close
40.10p
Trade high
40.90p
Volume
38,638
Year high
137.00p
Year low
36.00p
Dividend yield
–
Market capitalisation
£27.86 mn
P/E ratio
1.19
ISIN
FR0010397232
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 25/04/2025 | 03:56:38 | 38.2929 | 1,043 | 399.39 |
| 25/04/2025 | 01:07:50 | 39.4529 | 1,589 | 626.91 |
| 25/04/2025 | 12:09:33 | 39.8248 | 10,000 | 3,982.48 |
| 25/04/2025 | 12:02:20 | 39.45 | 300 | 118.35 |
| 25/04/2025 | 12:00:04 | 39.5 | 10,000 | 3,950.00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.